Vidarbha News

Major Depressive Disorder Market Insight, Epidemiology And Market Forecast -2030

 Breaking News
  • No posts were found

Major Depressive Disorder Market Insight, Epidemiology And Market Forecast -2030

August 06
19:13 2021
Major Depressive Disorder Market Insight, Epidemiology And Market Forecast -2030
DelveInsight Business Research LLP
DelveInsight’s “Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Major Depressive Disorder, historical and forecasted epidemiology as well as the Major Depressive Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

What is Major Depressive Disorder?

Major Depressive Disorder (MDD), also referred as depression, is a serious medical illness that disrupts a person’s mood, behavior, thought processes, apart from degrading the physical health.

How Major Depressive Disorder affected population?

Major Depressive Disorder Epidemiology

  • The most prevalent cases of Major Depressive Disorder (MDD) were recorded in the United States.
  • Among the European 5 countries, France had highest prevalent population of Major Depressive Disorder (MDD), followed by Germany and Spain. On the other hand, the United Kingdom had the lowest prevalent population of Major Depressive Disorder (MDD)
  • The third most prevalent cases of Major Depressive Disorder (MDD) in 7MM were recorded in Japan.

To know more, request sample pages of Major Depressive Disorder Market @ https://www.delveinsight.com/report-store/major-depressive-disorder-market

Major Depressive Disorder Market Outlook

The various major American and European guidelines for the treatment of depression provide similar basic principles of treatment, which include individualizing the treatment plan, preparing the patient for potential long-term treatment, providing measurement-based care, and treating to remission.

The new evidence-based guideline summarizes recommendations on the use of antidepressants and other drug therapies; psychotherapy, including cognitive behavior therapy; and Electroconvulsive Therapy (ECT).

Apart from therapies, companies are also focussed on the development of technologies that could further assist in the better management of the disease. BrainsWay’s Deep TMS received FDA clearance in 2018 to treat MDD. Deep TMS works by utilizing a magnetic field that manages to directly reach wider and deeper brain regions, regulating the neural activity of brain structures related to depression – specifically the dorsolateral prefrontal cortex (DLPFC).

Major-Depressive-Disorder

What are the Major Depressive Disorder Market Drivers?

Introduction of new pathway, increasing awareness on depression, and increasing spending on branded drugs are the present Major Depressive Disorder market drivers.

What are the Major Depressive Disorder Market Barriers?

Challenges in diagnoses, economic burden, and generic products are the Major Depressive Disorder market barriers.

Which are the leading companies in Major Depressive Disorder market?

The emerging treatment options in Major Depressive Disorder Market Landscape aim to improve the responses which are inadequate with respect to standard antidepressant therapies. Companies such as Axsome Therapeutics, SAGE Therapeutics, J&J/ Minerva Neurosciences, Intra-Cellular Therapies, and others are developing the therapies to transform the Major Depressive Disorder treatment scenario.

Table of contents

1. Key Insights

2. Executive Summary of Major Depressive Disorder

3. Competitive Intelligence Analysis for Major Depressive Disorder

4. Major Depressive Disorder: Market Overview at a Glance

4.1. Major Depressive Disorder Total Market Share (%) Distribution in 2017

4.2. Major Depressive Disorder Total Market Share (%) Distribution in 2030

5. Major Depressive Disorder: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Major Depressive Disorder Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Major Depressive Disorder Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Major Depressive Disorder Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Major Depressive Disorder Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Major Depressive Disorder Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Major Depressive Disorder Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Major Depressive Disorder Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Major Depressive Disorder Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Major Depressive Disorder Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Major Depressive Disorder Treatment and Management

8.2. Major Depressive Disorder Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Major Depressive Disorder Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Major Depressive Disorder: Seven Major Market Analysis

13.1. Key Findings

13.2. Major Depressive Disorder Market Size in 7MM

13.3. Major Depressive Disorder Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Major Depressive Disorder Total Market Size in the United States

15.1.2. Major Depressive Disorder Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Major Depressive Disorder Total Market Size in Germany

15.3.2. Major Depressive Disorder Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Major Depressive Disorder Total Market Size in France

15.4.2. Major Depressive Disorder Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Major Depressive Disorder Total Market Size in Italy

15.5.2. Major Depressive Disorder Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Major Depressive Disorder Total Market Size in Spain

15.6.2. Major Depressive Disorder Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Major Depressive Disorder Total Market Size in the United Kingdom

15.7.2. Major Depressive Disorder Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Major Depressive Disorder Total Market Size in Japan

15.8.3. Major Depressive Disorder Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Major Depressive Disorder

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request sample pages for more information on Major Depressive Disorder Market @ https://www.delveinsight.com/sample-request/major-depressive-disorder-market

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/